Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bettina Altmann

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Applied Optics|September 11, 2019
Alignment strategy for an optomechanical image derotator using a laser Doppler vibrometerBettina Altmann, Tim Betker, Christian Pape, et al.
Plos One|March 21, 2018
Impact of different supply air and recirculating air filtration systems on stable climate, animal health, and performance of fattening pigs in a commercial pig farmCindy Wenke, Janina Pospiech, Tobias Reutter, et al.
Ejhaem|July 18, 2022
Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: Results from prospective trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupKarin Hohloch, Marita Ziepert, Lorenz Truemper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximabJörg Thomas Bittenbring, Frank Neumann, Bettina Altmann, et al.
Annals of Hematology|November 26, 2020
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group)Florian Zettl, Marita Ziepert, Bettina Altmann, et al.
Leukemia|March 28, 2024
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trialMichael Oertel, Marita Ziepert, Fabian Frontzek, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
Annals of Hematology|September 3, 2024
An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphomaKonstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Vadim Lesan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Applied Optics|September 11, 2019
Alignment strategy for an optomechanical image derotator using a laser Doppler vibrometerBettina Altmann, Tim Betker, Christian Pape, et al.
Plos One|March 21, 2018
Impact of different supply air and recirculating air filtration systems on stable climate, animal health, and performance of fattening pigs in a commercial pig farmCindy Wenke, Janina Pospiech, Tobias Reutter, et al.
Ejhaem|July 18, 2022
Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: Results from prospective trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupKarin Hohloch, Marita Ziepert, Lorenz Truemper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximabJörg Thomas Bittenbring, Frank Neumann, Bettina Altmann, et al.
Annals of Hematology|November 26, 2020
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group)Florian Zettl, Marita Ziepert, Bettina Altmann, et al.
Leukemia|March 28, 2024
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trialMichael Oertel, Marita Ziepert, Fabian Frontzek, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
Annals of Hematology|September 3, 2024
An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphomaKonstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Vadim Lesan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2021
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Gerhard Held, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Pageof 3